Katya Tsaioun, Ph.D.
Apredica
ADDME – Avoiding Drug Development Mistakes Early
According to a study by the Tufts Center for the Study of Drug Development, the most productive drug discovery companies share several key attributes, one of which, speed, is so integral that Tufts calls these companies the “Speed Demons” of drug discovery. Speed of drug development turns out to be highly correlated with greater discovery success, lower development costs, and higher product revenues. The Speed Demons’ principal way to achieve speed is through avoiding drug development mistakes early in the drug-development process.
In this talk Dr. Tsaioun will outline the drug discovery industry’s productivity problems and introduce a few toxicity assays that should be applied at the lead optimization stage. Then to illustrate the application of the early toxicity and other ADME properties assessment, a series of contrasting case studies will be presented, showing how example Speed Demon companies addressed preclinical development and comparing them to case studies from less successful companies.